Results 31 to 40 of about 399,116 (301)

Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with Sorafenib with or without Erlotinib in the SEARCH Trial [PDF]

, 2016
Purpose: Sorafenib is the current standard therapy for advanced HCC, but validated biomarkers predicting clinical outcomes are lacking. This study aimed to identify biomarkers predicting prognosis and/or response to sorafenib, with or without erlotinib,
Evans, T.R. Jeffrey, Gane, Edward, Jeffers, Michael, Kang, Yoon-Koo, Meinhardt, Gerold, Peña, Carol E.A., Rosmorduc, Olivier, Ross, Paul, Santoro, Armando, Vogel, Arndt, Zhu, Andrew X.   +10 more
core   +1 more source

Biomarkers in sepsis. [PDF]

, 2013
Purpose of review: This review discusses the current developments in biomarkers for sepsis. Recent findings: With quantum leaps in technology, an array of biomarkers will become available within the next decade as point-of-care tools that will likely ...
Singer, M
core   +1 more source

ST2 and Multimarker Testing in Acute Decompensated Heart Failure [PDF]

, 2015
Most data on heart failure biomarkers have been derived from patient cohorts with chronic disease. However, risk prediction in patients admitted with acute decompensated heart failure (ADHF) remains a challenge.
Antoni, Md, Bayes, Genis, DI SOMMA, Salvatore, Maisel, Alan S., Md,, Md,, Md,, Mebazaa, Alexandre   +7 more
core   +1 more source

Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights

Journal of Hepatocellular Carcinoma, 2023
James Yu,1 Robin Park,1 Richard Kim2 1Division of Hematology and Medical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 2Department of Gastrointestinal Oncology, H.
Yu J, Park R, Kim R
doaj  

Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma [PDF]

, 2015
Accurate assessment of neuroblastoma outcome prediction remains challenging. Therefore, this study aims at establishing novel prognostic tumor DNA methylation biomarkers.
, Berbegall, Ana P., Bienertova-Vasku, Julie, Bown, Nick, Cannoodt, Robrecht, Clément, Nathalie, Combaret, Valérie, De Preter, Katleen, De Wilde, Bram, Decock, Anneleen, Haber, Michelle, Hoyoux, Claire, Laureys, Geneviève, Murray, Jayne, Noguera, Rosa, Ongenaert, Maté, Pierron, Gaelle, Schleiermacher, Gudrun, Schulte, Johannes H., Speleman, Frank, Stallings, Ray L., Tweddle, Deborah A., Van Roy, Nadine, Vandesompele, Jo, Verniers, Kimberly   +24 more
core   +2 more sources

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib [PDF]

, 2016
ARQ 197-215 was a randomized placebo-controlled phase II study testing the MET inhibitor tivantinib in second-line hepatocellular carcinoma (HCC) patients. It identified tumor MET as a key biomarker in HCC.
Abbadessa, Giovanni, Borbath, Ivan, Daniele, Bruno, De Toni, Enrico N, Gasbarrini, Antonio, Lamar, Maria E, Lencioni, Monica, Miles, Steven, Personeni, Nicola, Porta, Camillo, Rimassa, Lorenza, Salvagni, Stefania, Santoro, Armando, Schwartz, Brian E, Shuster, Dale, Trojan, Jörg, Van Laethem, Jean-Luc, Van Vlierberghe, Hans, Wang, Yunxia, Weiss, Alan   +19 more
core   +4 more sources

MMP2 as an independent prognostic stratifier in oral cavity cancers

OncoImmunology, 2020
Background Around 25% of oral cavity squamous cell carcinoma (OCSCC) are not controlled by the standard of care, but there is currently no validated biomarker to identify those patients. Our objective was to determine a robust biomarker for severe OCSCC,
Caroline Hoffmann, Sophie Vacher, Philémon Sirven, Charlotte Lecerf, Lucile Massenet, Aurélie Moreira, Aurore Surun, Anne Schnitzler, Jerzy Klijanienko, Odette Mariani, Emmanuelle Jeannot, Nathalie Badois, Maria Lesnik, Olivier Choussy, Christophe Le Tourneau, Maude Guillot-Delost, Maud Kamal, Ivan Bieche, Vassili Soumelis   +18 more
doaj   +1 more source

The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension [PDF]

, 2015
We assessed the predictive ability of selected biomarkers using N-terminal pro-brain natriuretic peptide (NT-proBNP) as the benchmark and tried to establish a multi-biomarker approach to heart failure (HF) in hypertensive patients. In 120 hypertensive
Agata Bielecka-Dabrowa, Anna Gluba-Brzózka, Campeau, Jacek Rysz, Li, Maciej Banach, Marta Michalska-Kasiczak, Małgorzata Misztal, McCullough, Ravassa, Wei   +10 more
core   +2 more sources

Prediction of acute coronary syndromes by urinary proteome analysis. [PDF]

PLoS ONE, 2017
Identification of individuals who are at risk of suffering from acute coronary syndromes (ACS) may allow to introduce preventative measures. We aimed to identify ACS-related urinary peptides, that combined as a pattern can be used as prognostic biomarker.
Nay M Htun, Dianna J Magliano, Zhen-Yu Zhang, Jasmine Lyons, Thibault Petit, Esther Nkuipou-Kenfack, Adela Ramirez-Torres, Constantin von Zur Muhlen, David Maahs, Joost P Schanstra, Claudia Pontillo, Martin Pejchinovski, Janet K Snell-Bergeon, Christian Delles, Harald Mischak, Jan A Staessen, Jonathan E Shaw, Thomas Koeck, Karlheinz Peter   +18 more
doaj   +1 more source

Identification of COPA as a potential prognostic biomarker and pharmacological intervention target of cervical cancer by quantitative proteomics and experimental verification

Journal of Translational Medicine, 2022
Background Cervical cancer is the most fatal gynecological carcinoma in the world. It is urgent to explore novel prognostic biomarkers and intervention targets for cervical cancer.
Huiqiong Bao, Xiaobin Li, Zhixing Cao, Zhihong Huang, Li Chen, Mingbing Wang, Jiali Hu, Wenting Li, Hongwei Sun, Xue Jiang, Ping Mei, Huawen Li, Ligong Lu, Meixiao Zhan   +13 more
doaj   +1 more source